Answers are grounded in this paper and cite their sources.
Integrated analysis identifies 1,5-disubstituted tetrazoles as potential agents against cancer drug resistance, suggesting new drug candidates.
The 1,5-disubstituted tetrazole (1,5-DS-T) scaffold is recognized as a privileged structure in medicinal chemistry due to its broad interaction potential with biologically relevant targets. In this study, we conducted an integrated chemoinformatic and molecular modeling analysis of 1,5-DS-T compounds from PubChem, ChEMBL, DrugBank, and an in-house library. Principal component analysis and scaffold diversity analyses showed that the in-house compounds occupy a region of chemical space largely overlapping with bioactive ChEMBL tetrazoles, while also revealing opportunities for further scaffold diversification. Analysis of pIC50 values and annotated therapeutic targets highlighted the broad bioactivity profile of 1,5-DS-T across pharmacologically relevant protein classes. Ligand-based target prediction combined with k-means clustering suggested CXCR3, a chemokine receptor implicated in cancer drug resistance, as a plausible target for the in-house collection. Subsequent molecular docking studies prioritized IH-114 as the most promising computational hit, and Boltz-2 analysis supports the proposed CXCR3 binding. Finally, we found that only a small fraction of bioactive 1,5-DS-T compounds were synthesized via the Ugi-azide reaction, a modular chemical strategy, central to our research work. This highlights the need for further exploration and synthesis of new 1,5-disubstituted tetrazole-based scaffolds via isocyanide-based multicomponent reactions to explore new regions of the chemical space and discover novel drug candidates targeting chemoresistant diseases.
No takes yet. Share an insight, caveat, or question.
Garibay-Manríquez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: